Ascidian Therapeutics’ Post

🚀 Exciting Developments in Clinical Trials 2024! 🌐 Here's a snapshot of what to expect: ▶️ Personalized Medicine Takes the Lead: Witness a shift towards tailored treatments, promising more effective and targeted outcomes. ▶️ Digital Transformation in Trials: Embrace the wave of tech-driven trials, utilizing digital tools for enhanced efficiency and accessibility. ▶️ Global Collaboration Beyond Borders: Expect increased collaboration across nations, enriching data diversity and broadening the impact of research findings. ▶️ Biopharmaceutical Revolution: Explore rapid advances in gene and cell therapies, with a focus on novel biopharmaceuticals that redefine treatment paradigms. ▶️ Patient-Centric Approach: 2024 marks a heightened commitment to patient experience, ensuring trials are designed around their needs for improved compliance and reliable results. At MZD, we're dedicated to connecting top-tier talent with organizations driving these transformative clinical trials. If you're passionate about shaping the future of medicine, reach out! Let's make a difference together. 💡🌟 #ClinicalTrials #HealthcareInnovation #MedicalRecruitment #2024Trends #JoinTheFuture

🚨 BioFuture™ 2024 Early-Bird Registration ends TODAY, September 30!  🌟 Early-Bird Registration here: https://lnkd.in/e2Qfb2Pr Be part of #BioFuture2024 from October 28-30 at Cure. in #NYC and position your company in front of top-tier venture and strategic investors and large pharma and biotech partners. Your registration includes full access to 100+ future-focused speakers on key industry topics and trends, as well as the opportunity to join 80+ presenting companies. With Early-Bird pricing ending today, September 30, apply now to secure your presentation slot and schedule one-on-one meetings.    📋 List of 2024 Registered Investors: https://lnkd.in/ewxccgxx   🎤 Apply to Present: https://lnkd.in/en3cYnXm This is a unique opportunity to increase your company's visibility, gain valuable media coverage, and connect with key decision-makers from organizations like Moderna, IBM, Teva Pharmaceuticals, Regeneron, Ipsen, and Johnson & Johnson. Presentation slots are filling up fast in multiple therapeutic categories, including cell and gene therapy, large and small molecule therapeutics, digital health, AI, medical devices, TechBio, healthcare delivery, and more.       👉 Request your presentation slot today: https://lnkd.in/en3cYnXm     #Biotechnology #Biopharma #AI #DigitalHealth #DrugDevelopment #Therapeutics #ResearchAndDevelopment #Innovation #VC #VCFunding #Partnering #BiotechLeaders #Cure #DemyColton

Part 1 has landed! Join in on their conversation on the Cell and Gene Therapy industry. Some topics that Darwin and Rajiv discuss in this episode are: - The current status of cell and gene therapy approvals, - CMC challenges - AAV-based gene therapy https://lnkd.in/eqi7xSkh Stay tuned to part 2 of their conversation. Remember to subscribe to the podcast to get the latest releases. #cellandgenetherapy #biotech #quality #CMC

🚀 Exciting Partnership Unveiled! Remix Therapeutics joins forces with Roche for pioneering discoveries in small molecule therapeutics modulating RNA processing using the REMaster™ platform. 🧬💊 🌐 Remix, a clinical-stage biotech, will receive $30 million upfront, with potential milestone payments totaling up to $1 billion, plus royalties. In return, Roche gains exclusive rights to specific targets, marking a strategic collaboration to advance RNA-level interventions in disease treatment. 💡👥 👨🔬 Peter Smith, CEO of Remix, expresses enthusiasm about leveraging REMaster's capabilities, stating, "Our collaboration with Roche provides an opportunity to further translate our cutting-edge science into new medicines." 🌱 🌐 James Sabry, Global Head of Roche Pharma Partnering, highlights Remix's scientific prowess, emphasizing the alignment with Roche's strategy to innovate in areas with high unmet medical needs. 🤝🔍 🔬 Remix Therapeutics, with its REMaster platform, aims to reprogram RNA processing to alter gene expression fundamentally—a potential game-changer in addressing disease drivers at their root. 🌍🔬 💬 Stay tuned for groundbreaking developments as Remix and Roche redefine the landscape of small molecule therapeutics! 💪🌐 #RemixTherapeutics #RocheCollaboration #RNAProcessing #BiotechInnovation #HealthcarePartnership #DrugDiscovery #MedicalAdvancements #InnovationInMedicine #Biopharma #REMmasterPlatform #LinkedInNews 🌐👩⚕️

The future of #molecular_glue discovery is characterized by a convergence of #AI, data science, and innovative approaches that are reshaping the landscape of drug discovery. From rational design and generative modeling to the exploration of stabilizing molecular glues and the integration of machine learning and cryo-EM, the field is poised for unprecedented advancements. As researchers continue to push the boundaries of molecular glue discovery, the potential for #unlocking #undruggable targets and expanding the therapeutic arsenal remains within reach, offering new hope for addressing unmet medical needs and driving the next wave of precision medicine. Contact us via #email at support@desertconsultingservice.com or direct message to receive a free sample of the 2024 Molecular Glue Pipeline Analytics. Know more of about the upcoming advancements in the Molecular Glue Discovery at the upcoming Molecular Glue Drug Development Summit 2024 https://lnkd.in/d4PRRZmz Promega Corporation ; Amgen; Ambagon Therapeutics; Lyterian Therapeutics; Monte Rosa Therapeutics; TRIANA Biomedicines; Gandeeva Therapeutics; Proxygen

🔬 Just wrapped up an incredible experience at the xRNA Therapeutics Development and Innovation Forum 2024! 🌐 Grateful for the opportunity to participate in this cutting-edge conference, where over 1000 professionals converged to explore the latest trends and innovations in biotech drug development. 🚀 Key Takeaways: 💡 Explored advancements in mRNA/circRNA vaccine/drug development. 🤖 Discovered the role of AI in accelerating mRNA research. 🌱 Explored emerging trends in oligonucleotide drug development. Notable Moments: Engaging discussions on mRNA delivery strategies and quality control. Insightful presentations by industry leaders on CRISPR/Cas9 applications and mRNA nano-tumor vaccines. Gratitude: Huge thanks to Deliver Life Sciences and all supporting units for organizing this impactful event! 🙌 Looking Forward: Excited to bring these insights back to the team and explore potential collaborations in line with the discussed strategies. The future of biotech is indeed thrilling! 🌟 #Biotech #DrugDevelopment #Innovation #Networking #ConferenceExperience #LinkedInPost

"Drug development teams have found significant data and modeling challenges in regard to tackling the complexities associated with #PDIinhibitors given the challenges with creating meaningful models, and accumulating and deciphering the data," said Panna Sharma, CEO and President of Lantern Pharma. "Our #AI platform, RADR®, can increase the confidence, insights, and comfort levels in developing data-driven development paths by modeling highly complex scenarios at a scale that only has become possible recently. It’s an ideal approach for Oregon Therapeutics, which has executed a series of highly targeted in vivo and in vitro experiments and is poised to make incredibly important and patient-centric decisions about the clinical future of the molecule. That's where RADR® can play a highly essential and market defining role." https://lnkd.in/gabi_27S #biotech #businessdevelopment #artificialintelligence

"Drug development teams have found significant data and modeling challenges in regard to tackling the complexities associated with #PDIinhibitors given the challenges with creating meaningful models, and accumulating and deciphering the data," said Panna Sharma, CEO and President of Lantern Pharma. "Our #AI platform, RADR®, can increase the confidence, insights, and comfort levels in developing data-driven development paths by modeling highly complex scenarios at a scale that only has become possible recently. It’s an ideal approach for Oregon Therapeutics, which has executed a series of highly targeted in vivo and in vitro experiments and is poised to make incredibly important and patient-centric decisions about the clinical future of the molecule. That's where RADR® can play a highly essential and market defining role." https://lnkd.in/gabi_27S #biotech #businessdevelopment #artificialintelligence

📣ESACT 2024 is right around the corner, and we’d love to see you there! Looking to drive up productivity and drive down manufacturing COGS? Don’t miss our presentations: ✔Poster Presentation: Evaluation of Small Molecule Antagonists of Cellular Innate Immunity for Efficient Manufacturing of T-cell Therapeutics. (Ranked among the top 100 posters!) Session 3: June 25th 2:30-4:00 PM ✔Poster Presentation: Dual Technology Intensification-Fixed Bed Bioreactor Technology Combined with Viral Sensitizers for Adherent Cell Lines. Session 2: June 24th 7:30-9:00 PM ✔Oral Presentation: High-Throughput Virology and Design of Experiment for Rapid Vector Production Process Optimization. Check out our exciting collaboration data with Cytiva demonstrating robust 2x yield enhancement using our VSEᵀᴹ Technology on Cytiva's iCELLisᵀᴹ Nano Bioreactor. 💡 Learn how we leverage the power of Viral Sensitizers (VSEs), high-throughput virology, and Design of Experiments (DoE) to rapidly optimize viral vector production and boost viral yields. 🤝 Connect with us to learn more: https://lnkd.in/gD4g8f94 #ESACT2024 #biomanufacturing #innovation